101 related articles for article (PubMed ID: 3485325)
1. Comparisons of pooled polyclonal rabbit anti-human C3d with four monoclonal mouse anti-human C3ds. I. Preparation, purification and binding properties.
Chaplin H; Monroe MC
Vox Sang; 1986; 50(1):42-51. PubMed ID: 3485325
[TBL] [Abstract][Full Text] [Related]
2. Comparisons of pooled polyclonal rabbit anti-human C3d with four monoclonal mouse anti-human C3ds. II. Quantitation of RBC-bound C3d, and characterization of antiglobulin agglutination reactions against RBC from 27 patients with autoimmune hemolytic anemia.
Chaplin H; Monroe MC
Vox Sang; 1986; 50(2):87-93. PubMed ID: 2421484
[TBL] [Abstract][Full Text] [Related]
3. Monoclonal antibodies against complement 3 neoantigens for detection of immune complexes and complement activation. Relationship between immune complex levels, state of C3, and numbers of receptors for C3b.
Aguado MT; Lambris JD; Tsokos GC; Burger R; Bitter-Suermann D; Tamerius JD; Dixon FJ; Theofilopoulos AN
J Clin Invest; 1985 Oct; 76(4):1418-26. PubMed ID: 2932466
[TBL] [Abstract][Full Text] [Related]
4. Epitope specificities and quantitative and serologic aspects of monoclonal complement (C3c and C3d) antibodies.
Dobbie D; Brazier DM; Gardner B; Holburn AM
Transfusion; 1987; 27(6):453-9. PubMed ID: 2446405
[TBL] [Abstract][Full Text] [Related]
5. Quantification of antibodies to the C3d subcomponent of human C3.
Chaplin H; Freedman J; Hughes-Jones NC
Immunology; 1977 Jun; 32(6):1007-15. PubMed ID: 301852
[TBL] [Abstract][Full Text] [Related]
6. Isolation and analysis of complement activating aggregates from synovial fluid of patients with rheumatoid arthritis using monoclonal anti-C3d antibodies.
Bedwell AE; Elson CJ; Carter SD; Dieppe PA; Hutton CW; Czudek R
Ann Rheum Dis; 1987 Jan; 46(1):55-64. PubMed ID: 3492971
[TBL] [Abstract][Full Text] [Related]
7. C3d,g is present in normal human epidermal basement membrane.
Basset-Seguin N; Dersookian M; Cehrs K; Yancey KB
J Immunol; 1988 Aug; 141(4):1273-80. PubMed ID: 3135326
[TBL] [Abstract][Full Text] [Related]
8. A prospective study of circulating immune complexes in patients with breast cancer.
Bukh A; Aguado MT; Krarup N; Poulsen HS; Nordentoft AM; Møller NP
Int J Cancer; 1988 Mar; 41(3):364-70. PubMed ID: 3257943
[TBL] [Abstract][Full Text] [Related]
9. NBTS/BRIC 8. A monoclonal anti-C3d antibody.
Holt PD; Donaldson C; Judson PA; Johnson P; Parsons SF; Anstee DJ
Transfusion; 1985; 25(3):267-9. PubMed ID: 3873730
[TBL] [Abstract][Full Text] [Related]
10. Identification of the membrane receptor for the complement fragment C3d by means of a monoclonal antibody.
Iida K; Nadler L; Nussenzweig V
J Exp Med; 1983 Oct; 158(4):1021-33. PubMed ID: 6225820
[TBL] [Abstract][Full Text] [Related]
11. Epitope mapping using the X-ray crystallographic structure of complement receptor type 2 (CR2)/CD21: identification of a highly inhibitory monoclonal antibody that directly recognizes the CR2-C3d interface.
Guthridge JM; Young K; Gipson MG; Sarrias MR; Szakonyi G; Chen XS; Malaspina A; Donoghue E; James JA; Lambris JD; Moir SA; Perkins SJ; Holers VM
J Immunol; 2001 Nov; 167(10):5758-66. PubMed ID: 11698449
[TBL] [Abstract][Full Text] [Related]
12. [Circulating immune complexes and anti-IgG antibodies in rheumatoid disease. Value of C3d assay].
Duquesnoy B; Santoro F; Siame JL; Vanhille P; Raviart B; Wattre P; Lemaitre V; Hatron PY
Rev Med Interne; 1981; 2(1):11-6. PubMed ID: 6972076
[No Abstract] [Full Text] [Related]
13. A simple method for the production of anti-C3d monoclonal antibody.
Cruz C; León G
Hybridoma (Larchmt); 2007 Dec; 26(6):433-4. PubMed ID: 18158789
[TBL] [Abstract][Full Text] [Related]
14. Conformational differences between surface-bound and fluid-phase complement-component-C3 fragments. Epitope mapping by cDNA expression.
Nilsson B; Grossberger D; Nilsson Ekdahl K; Riegert P; Becherer DJ; Nilsson UR; Lambris JD
Biochem J; 1992 Mar; 282 ( Pt 3)(Pt 3):715-21. PubMed ID: 1372802
[TBL] [Abstract][Full Text] [Related]
15. Direct quantitation of activated C3 in human plasma with monoclonal anti-iC3b-C3d-neoantigen.
Kanayama Y; Kurata Y; McMillan R; Tamerius JD; Negoro N; Curd JG
J Immunol Methods; 1986 Apr; 88(1):33-6. PubMed ID: 2420896
[TBL] [Abstract][Full Text] [Related]
16. Plasma concentrations of complement split product C3d and immune complexes after procainamide induced production of antinuclear antibodies.
Brandslund I; Ibsen HH; Klitgaard NA; Svehag SE; Simonsen E; Diederichsen H
Acta Med Scand; 1986; 220(5):431-5. PubMed ID: 3492864
[TBL] [Abstract][Full Text] [Related]
17. C3d fragment of complement interacts with laminin and binds to basement membranes of glomerulus and trophoblast.
Leivo I; Engvall E
J Cell Biol; 1986 Sep; 103(3):1091-100. PubMed ID: 3488995
[TBL] [Abstract][Full Text] [Related]
18. Activation of human platelets through gp140, the C3d/EBV receptor (CR2).
Nunez D; Charriaut-Marlangue C; Barel M; Benveniste J; Frade R
Eur J Immunol; 1987 Apr; 17(4):515-20. PubMed ID: 2952514
[TBL] [Abstract][Full Text] [Related]
19. Studies of C3d,g in normal human epidermal basement membrane.
Yancey KB; Basset-Séguin N
J Invest Dermatol; 1990 Jun; 94(6 Suppl):122S-127S. PubMed ID: 2191048
[TBL] [Abstract][Full Text] [Related]
20. A modified competitive inhibition radioimmunoassay for the detection of C3a. Use of 125I-C3 instead of 125I-C3a.
Hack CE; Paardekooper J; Eerenberg AJ; Navis GO; Nijsten MW; Thijs LG; Nuijens JH
J Immunol Methods; 1988 Apr; 108(1-2):77-84. PubMed ID: 3258341
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
